Skip to main content
IMCR logo

IMCR · Immunocore Holdings plc · Earnings Calls, Transcripts & Webcasts

Track IMCR — free
$26.41 -0.22 (-0.83%) At close · Nov 20 Q4 2025 earnings call transcript
Market Cap
$1.36B
Shares
51.68M
Volume · Nov 20 546.2K Avg daily vol (3M) 449.07K

Immunocore Holdings plc Webcasts

Earnings calls, investor updates, investor days and conferences for Immunocore Holdings plc (IMCR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-11-17
Immunocore Holdings plc (IMCR) November 17, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-14
Immunocore Holdings plc (IMCR) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
Immunocore Holdings plc (IMCR) Q2 2026 Earnings Call
Revenue
$115.93M
▲ 18.3% YoY
Diluted EPS
$-0.02
Gross margin
99.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-13
Immunocore Holdings plc (IMCR) April 13, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-25
Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript
Confident tone KIMTRAK commercial performance Cutaneous melanoma opportunity Pipeline expansion and Phase 3 trials
Revenue
$104.48M*
▲ 24.3% YoY
Gross margin
97.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q2
2025-08-07
Immunocore Holdings plc (IMCR) Q2 2025 Earnings Call Transcript
Confident tone TEBE-AM Phase III in second-line cutaneous melanoma KIMMTRAK commercial performance and global expansion U.S. market dynamics and duration of therapy
Revenue
$97.96M
▲ 29.9% YoY
Diluted EPS
$-0.20
Gross margin
98.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-10
Immunocore Holdings plc (IMCR) Q4 2024 Earnings Call Transcript
Confident tone KymTrah commercial performance and growth Infectious disease pipeline (HIV / HBV) Autoimmune programs
Revenue
$84.05M*
▲ 19.8% YoY
Gross margin
99.6%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q2
2024-08-08
Immunocore Holdings plc (IMCR) Q2 2024 Earnings Call Transcript
Positive tone Pipeline and clinical readouts KIMMTRAK commercial performance European reimbursement challenges
Revenue
$75.40M
▲ 26.2% YoY
Diluted EPS
$-0.23
Gross margin
97.7%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-29
Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript
Confident tone PRAME franchise (F106C, PRISM-MEL301) KIMMTRAK commercial performance TEBE-AM Phase 2/3 trial in cutaneous melanoma
Revenue
$70.16M*
Gross margin
99.7%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q2
2023-06-30
Date not confirmed
Immunocore Holdings plc (IMCR) Q2 2023 Earnings Call Transcript
Revenue
$59.76M
Diluted EPS
$-0.35
Gross margin
99.4%
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Date not confirmed
Immunocore Holdings plc (IMCR) Q4 2022 Earnings Call Transcript
No reported figures on file
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q2
2022-06-30
Date not confirmed
Immunocore Holdings plc (IMCR) Q2 2022 Earnings Call Transcript
No reported figures on file
Audio Transcript Slides 8-K10-Q
Showing 1–12 of 12 webcasts
Key facts CIK 1671927 CUSIP 45258D105 13F (30d) 150 filings 122 filers Visit website Investor relations